title: Fulminant Aeromonas hydrophila infection during acute lymphoblastic leukemia treatment.
abstract: Aeromonas hydrophila septicemia has a fulminant course and it has been usually reported in immunocompromised hosts and rarely among children with leukemia. High morbidity and mortality is associated with A hydrophila infections. We describe the case of a child with acute lymphoblastic leukemia who presented with septicemia due to A hydrophila. The patient presented with fever and skin discoloration during a febrile neutropenia episode, which rapidly evolved into bacteremia and extensive thigh suppuration, fasciitis, and myonecrosis. Apart from antibiotic treatment, surgical debridement to relieve compartment pressure and prevent further lower extremity compromise was promptly performed. Despite long delays in chemotherapy and an extensive tissue gap, primary closure of the involved area was possible with full cosmetic and functional limb recovery, and the patient has remained in clinical remission for more than 7 years.
authors.affiliation: Department of Pediatric Hematology- Oncology Aghia Sophia Children's Hospital, Athens, Greece.
authors.forename: Vassilios
authors.initials: V
authors.lastname: Papadakis
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Poniros
authors.forename: Karerina
authors.initials: K
authors.lastname: Katsibardi
authors.forename: Athina-Eleni
authors.initials: AE
authors.lastname: Charissiadou
authors.forename: John
authors.initials: J
authors.lastname: Anastasopoulos
authors.forename: Sophia
authors.initials: S
authors.lastname: Polychronopoulou
mesh_terms: D016980:Aeromonas hydrophila / Q000302:isolation & purification*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D002675:Child, Preschool; D003646:Debridement; D005260:Female; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy / Q000382:microbiology* / Q000473:pathology / Q000601:surgery; D006801:Humans; D016867:Immunocompromised Host; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications* / Q000188:drug therapy*; D018805:Sepsis / Q000188:drug therapy / Q000382:microbiology* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents